Previous 10 | Next 10 |
2023-05-08 22:53:03 ET Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Conference Call May 08, 2023, 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&...
2023-05-08 16:13:37 ET Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q1 GAAP EPS of -$0.59 beats by $0.01 . As of March 31, 2023, Syndax had cash, cash equivalents, short- and long-term investments of $449.0 million and 69.6 million common shares and pr...
Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update PR Newswire – Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal...
Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023 PR Newswire WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company devel...
Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development PR Newswire - Neil Gallagher , M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer - WALTH...
Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients PR Newswire WALTHAM, Mass. , March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced tha...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass. , March 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative ...
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Results Conference Call February 28, 2023 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Briggs Morrison - President and Head, R&D Keith Goldan ...
Summary Syndax Pharmaceuticals, Inc. has two pivotal trials with data readouts coming up in 2023, with possible regulatory filings. They are loaded with cash after a successful offering. Despite current highs, I see further upside in 2023. Syndax Pharmaceuticals, Inc. ( ...
Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q4 GAAP EPS of -$0.62 beats by $0.04 . As of December 31, 2022, Syndax had cash, cash equivalents, short-term and long-term investments of $481.3 million and 69.3 million common shares and prefunded warrants outstandi...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress PR Newswire - Data continue to support revumenib's potential to enhance current standard of care agents - ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...